Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Recombinant Hepatitis B Vaccines in Chinese Neonates
NCT01183611Phase 3Completed
- Sponsor
- Jiangsu Provincial Center for Disease Control and Prevention
- Start
- Apr 2007
- Primary completion
- Jun 2010
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of hepatitis b vaccine recombinant in hepatitis B (HBV) (7 arms), sponsored by Jiangsu Provincial Center for Disease Control and Prevention. Primary endpoints: The immunogenicity of experimental recombinant HBV vaccines in healthy neonates on day 210 and The immunogenicity of experimental recombinant HBV vaccines in healthy neonates on day 360. Started Apr 2007; status: completed.
02
Drugs
hepatitis b vaccine recombinant
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT01183611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01183611.